Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary? (ICBN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32618
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) 1-3
- Distal upper extremity surgery with anticipated use of tourniquet
- Outpatient surgery
- Patients who desire regional anesthesia as primary anesthetic
Exclusion Criteria:
- ASA 4 or greater
- Allergies to local anesthetic
- Refusal of regional anesthesia
- History of chronic pain syndromes
- Patients who do not desire regional anesthesia as primary anesthetic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: ICBN with ropivacaine
Participants will receive ICBN with ropivacaine.
In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
|
ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
Other Names:
|
|
PLACEBO_COMPARATOR: No ICBN block
Participants will have the site prepped, but no ICBN block given.
In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
|
The site of injection will be prepped with tinted chlorhexidine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change between the 2 groups assessed by the incidence of tourniquet pain reported by the patient on a Descriptor Differential Scale of Pain Intensity (DDSI)
Time Frame: From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Tourniquet pain defined by the presence of dull or aching pain underneath the tourniquet
|
From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change between the 2 groups depth of anesthesia during surgery to alleviate tourniquet pain as assessed by the American Society of Anesthesiologist (ASA) Continuum of Depth of Sedation definition of general anesthesia and levels of sedation/analgesia.
Time Frame: From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Determine required depth of anesthesia during surgery to alleviate tourniquet pain
|
From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
|
Change between the 2 groups assessed by intraoperative opioid consumption
Time Frame: From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Determine amount of intraoperative opioid consumption due to tourniquet pain
|
From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
|
Change between the 2 groups assessed by time to onset of tourniquet pain
Time Frame: From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Determine the time to onset of tourniquet pain
|
From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
|
Change between the 2 groups in reported severity of tourniquet pain
Time Frame: From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Determine if ICBN has an affect on the severity of tourniquet pain as assessed by Descriptor Differential Scale of Pain Intensity (DDSI) There are 10 points along which patients can rate their pain intensity to the right and left of each descriptor, so the pain is rated on a 21 point scale for each descriptor.
Pain intensity is defined as a mean of the ratings and can range from 0 to 20.
|
From intraoperative pre tourniquet insufflation to intraoperative release of tourniquet (up to 2 hours)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Linda Le-Wendling, MD, University of Florida
Publications and helpful links
General Publications
- Satsumae T, Yamaguchi H, Inomata S, Tanaka M. Magnesium sulfate attenuates tourniquet pain in healthy volunteers. J Anesth. 2013 Apr;27(2):231-5. doi: 10.1007/s00540-012-1493-4. Epub 2012 Oct 7.
- Hagenouw RR, Bridenbaugh PO, van Egmond J, Stuebing R. Tourniquet pain: a volunteer study. Anesth Analg. 1986 Nov;65(11):1175-80.
- Valli H, Rosenberg PH, Kytta J, Nurminen M. Arterial hypertension associated with the use of a tourniquet with either general or regional anaesthesia. Acta Anaesthesiol Scand. 1987 May;31(4):279-83. doi: 10.1111/j.1399-6576.1987.tb02566.x.
- Crews JC, Cahall M, Behbehani MM. The neurophysiologic mechanisms of tourniquet pain. The activity of neurons in the rostroventral medulla in the rat. Anesthesiology. 1994 Sep;81(3):730-6. doi: 10.1097/00000542-199409000-00027.
- MacIver MB, Tanelian DL. Activation of C fibers by metabolic perturbations associated with tourniquet ischemia. Anesthesiology. 1992 Apr;76(4):617-23. doi: 10.1097/00000542-199204000-00020.
- Tschaikowsky K, Hemmerling T. Comparison of the effect of EMLA and semicircular subcutaneous anaesthesia in the prevention of tourniquet pain during plexus block anaesthesia of the arm. Anaesthesia. 1998 Apr;53(4):390-3. doi: 10.1046/j.1365-2044.1998.00301.x.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB201802525
- OCR19802 (OTHER: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.